Indian dermatology therapeutics Market reports

1. A sample report on Indian Dermatological Therapeutics Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2021 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the Indian Dermatology Therapeutics market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, characteristics, main players, trends and insights, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Indian Dermatology Therapeutics market, and offers unmatched value, accuracy, and expert insights

3. • Market Overview • Growth Drivers & Restraints • Major Dermatology Disease • Market Segmentation • Major Market Share • Competitive Landscape • Key Company Profiles • Healthcare Policies & Regulatory Framework • Factors Driving Future Growth • Conclusion Table of Contents

4. Table of Contents 1. Indian Dermatology Therapeutics Market Overview…………………………………………..…………………………………....…...........7 1.1 Background 1.2 Introduction 1.3 Market size and forecast 2. Market Growth Drivers and Restraints …………………………………………………………………….…………………………………….11 2.1 Market Growth Drivers 2.1.1 Increase in incidence of skin diseases 2.1.2 Awareness regarding skin diseases 2.1.3 Rising number of working women 2.1.4 Demand for topical dermatology drugs 2.1.5 Easy accessibility of the products 2.1.6 Government Initiatives 2.2 Market Restraints 2.2.1 Serious side effects of drugs 2.2.2 Competitors in Market 4 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

5. Table of Contents (continued) 3. Major Types of Dermatology Diseases…..…………………………………………………………………………………..………………..20 3.1 Eczema 3.2 Tinea Pedis 3.3 Urticaria/Angioedema 3.4 Atopic Dermatitis 3.5 Acne 4. Dermatology Market Segmentation………………………..…………………………………………………………………..……….….….23 4.1 By Disease Type 4.2 By Drug Class 4.3 By Route ofAdministration 4.4 By End Users 4.5 By Distribution Channel 5. Dermatology Major Products Market Share…………………………………………………………...…………..….......…………….….31 5.1 MarketAnalysis, Insights and Forecast - By Revenue 5 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

6. Table of Contents (continued) 6. Competitive Landscape……………………………………………………………………………………………………………….……………....33 6.1 Major Players 6.2 Products in Pipeline 7. Key Company Profiles (Company Overview, Product & Services, Strategies & Financials ) ….…………………………………..……..…...36 7.1 Sun Pharma 7.2 GlaxoSmithKline 7.3 Glenmark Pharmaceuticals 7.4 Galderma 7.5 USV Private Limited 8. Healthcare Policies and Regulatory Landscape………………………………….………………………………………………...……………..42 8.1 Regulatory Framework of Indian Dermatology Therapeutics Market 9. Factors Driving Future Growth………………………………………………………………………………………………………………….…...45 9.1 Future Opportunities 10. Conclusion……………………….…………………………………………………………………………………………………….………….…...47 10.1 Strategic Recommendations 6 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

7. Indian Dermatology Therapeutics Market Analysis 1. Overview

8. 1.1 Background Skin diseases are responsible for significant morbidity worldwide, but they do not get due importance in national health planning and policies in several countries. Although mortality due to skin diseases is low, they contribute to significant disability, and the non- fatal burden of skin and subcutaneous diseases is more than that of cardiovasculardiseases in India ▪ In India, there were 4.07 million (95% uncertainty interval 2.65–6.19 million) years lived with disability due to skin and subcutaneous diseases in 1990, which increased to 6.26 million (95% uncertainty interval 4.12-9.35 million) in 2017.Although the number of years lived with disability has increased by 53.7% between 1990 and 2017, the increase in age-standardised years lived with disability rates was only 1.52% ▪ The high burden of skin and subcutaneous diseasesdemand that they be given due importance in the national programmes and health policy of India ▪ 8 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

9. 1.2 Introduction As people age, the risk of developing skin-related disorders increases, due to factors, such as changes in the connective tissue, reduction in the skin’s strength and elasticity, and reduction in secretions from sebaceous glands ▪ Skin conditionspose a significant threat to patient’swell-being, mental health, ability to function, and social participation In India, Dermatitis (atopic, seborrheic and contact) contributed maximum to years lived with disability (1.40Mn, 95% uncertainty interval:0.82–2.21) followed by urticaria (1.02Mn, 95% uncertainty interval 0.06-1.44) with percentage increases of 48.9% and 45.7%, respectively Infections and infestations contributedto nearly 30 % of the total years lived with disability due to skin and subcutaneous diseases (fungal skin diseases- 12.6%, viral skin diseases-10.0% and scabies- 10.3%) ▪ ▪ ▪ 9 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

10. 1.3 Market Size & Forecast Key Analysis Indian Dermatology Therapeutics Market Size US$ Mn Indian Dermatology Therapeutics market size stood at around US$ xx Bn in 2021 and is projected to reach US$ xx Bn by 2030, exhibiting a CAGR of around xx% during the forecast period ▪ XX The derma market has grown by approximately 4.5% per year on an average (CAGR). The current market size of the Dermatology segments in India is approximately $xx Mn, growing rapidly at about xx%. In terms of revenue, the face care products was dominating the market with 57.22% share in 2020 ▪ xx The increasing incidence of Dermatology diseases and increasing levels of awareness-related disease progression, etiology, and available therapies are leading to a high growth of Dermatology therapeutics in India ▪ 2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F 10 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

11. Indian Dermatology Therapeutics Market Analysis 2. Growth Drivers & Restraints

12. 2.1 Market Growth Drivers Rise in the incidence of skin diseases Demand for Topical Dermatologydrugs Easy Awareness regarding Skin Diseases Market Drivers Accessibility of the products Rising number of working women Government Initiatives 12 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

13. Market Growth Drivers 2.1.1 Rise in the incidence of skin diseases With the rise in the aging population, Dermatology care is likely to receive particular attention • Sample As people age, the risk of developing skin- related disorders increases due to factors, such as changes in the connective tissue, reduction in the skin's strength and elasticity, and reduction in secretions from sebaceous glands • 13 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

14. Market Growth Drivers (continued) 2.1.2 Awareness regarding skin diseases Increase in improvement of awareness regarding skin health in India ▪ Sample Sample 14 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

15. Market Growth Drivers (continued) 2.1.3 Rising number of working women Rising number of working women and is leading to higher demand for personal care product ▪ Sample Sample Sample 15 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

16. Market Growth Drivers (continued) 2.1.4 Demand for Topical Dermatology drugs Demand for topical Dermatology drugs has increased due to increased population. It directly affects the growth of Dermatology Market • Sample Drugs such as anti-inflammatory agents, anti-infective, local anaesthetics, cleansers, and emollients to treat acne • Sample 16 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

17. Market Growth Drivers (continued) 2.1.5 Easy accessibility of the products Easy accessibility of the products through company websites and online channels, and doorstep delivery are driving the market • Sample Sample Sample 17 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

18. Market Growth Drivers (continued) 2.1.6 Government Initiatives The initiatives taken by the government are expected to contribute to the growth of the dermatology market in India ▪ For example, PMJY, is funded tertiary health coverage scheme, which provides cashless surgical treatments for various ailments, including Dermatology problems Sample ▪ Sample 18 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

19. 2.2 Market Restraints 2.2.2 Competitors in market 2.2.1 Serious side effects Due to the presence of numerous globally operating companies, the Indian skincare derma cosmetics market is fragmented, which is prompting the players to launch new products ▪ Serious side effects of certain classes of therapeutic drugs are expected to restrain the market growth in the near future ▪ Sample Sample 19 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

20. Indian Dermatology Therapeutics Market Analysis 3. Major Dermatology Diseases

21. 3. Major Dermatology Diseases 3.2 3.1 3.3 Eczema Urticaria⁄Angioedema Tinea Pedis Chronic urticaria is a relatively common condition in India and most cases have no specific allergic trigger and remain idiopathic In India, at least one in five children suffer from eczema, also known as atopic dermatitis. “Since the underlying causes are incompletely known, we undertook a study to identify correlates of the disease” About 10% of the total population may be affected by dermatophyte infections of the toe clefts Autoimmune causes have been found to be associated with up to 30- 40% cases The condition is more common in adult males than in females It is important to look for physical urticarias such as pressure urticaria in chronic cases 21 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

22. Major Dermatology Diseases 3.4 3.5 Acne Atopic Dermatitis In India, about 12 percent between 20 to 29 years of age had acne problems. Excess oil production, pores becoming clogged by sticky skin cells, bacteria and inflammationdirectly contributed to acne problems Atopic Dermatitis (AD) is hereditary and the most common type of eczema.AD almost always starts in infancy or before age 5 22 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

23. Indian Dermatology Therapeutics Market Analysis 4. Market Segmentation

24. Snapshot of Dermatology Therapeutics Market Segmentation By Disease Type By Drug Class Dermatology Market Segmentation By Route Of Administration By End Users By Distribution Type 24 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

25. Snapshot of Dermatology Therapeutics Market Segmentation ROUTE OF ADMINISTRA TION END USERS DISEASE TYPE DRUG CLASS DISTRIBUTION CHANNEL Anti-infectives Corticosteroid s Calcineurin inhibitors Retinoids Antirheumatic Oral Topical Parenteral Administratio n Acne Dermatitis Psoriasis Skin Cancer Alopecia Rosacea • • • • • Home Care Hospital Dermatolog y Clinics • • • • • • • Pharmacy Store Retail Store Online • • • • • • • • 25 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

26. 4.1 Market Segmentation: By Disease Type Indian Dermatology Therapeutic Market Share by Disease type 2022 Key Insights Approximately 80 percent of Indian are affected by acne between the onset of puberty and 30 years of age. By the end of 2026, the number of people affected by acne in India is estimated to reach 23 million at a compound annual growth rate (compound average growth rate) of 0.5 percent. ▪ SAMPLE In India, the incidence of melanoma of the skin in the North region is 1.62 for males and 1.21 for females for every 1,00,000 people. The overall incidence of nonmelanoma skin cancer is the highest in the Northeast region, going as high as 5.14 for men and 3.98 for women for every 1,00,000 people. ▪ Content ▪ Atopic Dermatiti s Acn e Eczem a Skin Cancer Tinea Pedis 26 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

27. 4.2 Market Segmentation: By Drug Type Indian Dermatology Therapeutics Market Share by Drug Type 2022 Key Insights The biologics segment is expanding at a large scale during the forecast period owing to the increasing regulatory approval of biologics. ▪ Anti-infectives are medicines that work to prevent or treat infections, they include antibacterials, antivirals, antifungals and antiparasitic medications. ▪ SAMPLE Topical corticosteroids are effective in a number of dermatoses. Dermatotherapy has always been a combination of art and science. ▪ Sample Calceneurin Inhibitors Retinoids Antirhematic Anti-infectives Corticosteroids 27 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

28. 4.3 Market Segmentation: Route of Administration Indian Dermatology Therapeutic Market Share by Route of Administration, 2022 Key Insights In Indian dermatology therapeutics market, the topical segment held a large share of the market owing to the rise in the demand for topical Dermatology drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients to treat acne. ▪ Parenteral administration SAMPLE Oral Topical Topical Oral Parenteral administration 28 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

29. 4.4 Market Segmentation: By End Users Indian Dermatology Therapeutic Market Share by End User, 2022 Key Insights Hospitals provide medical, diagnostic, and treatment services to inpatients and some outpatient dermatology services, which is holding largest share of the dermatology market ▪ Large number patients are being treated at home, which is holding market share following hospitals in dermatology market SAMPLE ▪ Hospitals Homecare DermatologyClinics 29 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

30. 4.5 Market Segmentation: By Distribution Channels Indian Dermatology Therapeutic Market Share by Distribution Channel, 2022 Key Insights It is expected that the pharmacy and retail store category will lead throughout the forecast period. ▪ This is due to the availability of a broad range of over-the- counter derma products, which are available in the pharmacy and retail stores. ▪ SAMPLE However, with the increasing trend toward online shopping and due to Covid-19 impact, people are preferring to make an online purchase and due to this online category is also witnessing faster growth in the dermatology market ▪ Pharmacy Store Retail Store Online 30 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

31. Indian Dermatology Therapeutics Market Analysis 5. Major Product Market Share

32. 5.1 Major Dermatology Products Market Share Indian Dermatology Therapeutics Major Products Market Share Key Insights SAMPLE Top Brands in Dermatology Therapeutics Market Brand 1 Brand 2 Brand3 Brand4 44 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

33. Indian Dermatology Therapeutics Market Analysis 6. Competitive Landscape

34. 6.1 Major Players Revenue (Current and Forecast) Revenue of Major Dermatology Market Players ($Bn) 2021 2022F 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX Sun Pharma GlaxoSmithKline $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX Glenmark Pharmaceuticals $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX Galderma India Private Limited $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX USV Private Limited. $XX $XX $XX $XX $XX $XX $XX $XX $XX $XX 34 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

35. 6.2 Products in Pipeline Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray- based AKVANO technology ▪ Content Sample 48 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

36. Indian Dermatology Therapeutics Market Analysis 7. Key Company Profiles

37. 7.1 Sun Pharma Company Profile Company Name: Sun Pharma Year of Establishment: 1983 Headquarter: India Revenue: $4.5 Bn Website www.sunpharma.com Sample 37 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

38. 7.2 GlaxoSmithKline Company Profile Company Name: GlaxoSmithKline Year of Establishment: 2000 Headquarter: United Kingdom Revenue: $xx Bn Website: www.gsk.com Sample 38 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

39. 7.3 Glenmark Pharmaceuticals Company Profile Company Name: Glenmark Pharmaceuticals Year of Establishment: 1977 Headquarter: Mumbai, India Revenue: $xx Bn Website: www.glenmarkpharma.com Sample 39 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

40. 7.4 Galderma India Private Limited Company Profile Company Name: Galderma India Private Limited Year of Establishment: 1981 Headquarter: SA Lausanne, Switzerland Revenue: $3.4 Bn www.galderma.com Website: Sample 40 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

41. 7.5 USV Private Limited Company Profile Company Name: USV Private Limited Year of Establishment: 1959 Headquarter: Mumbai, India Revenue: $2.3 Bn Website: www.usvindia.com Sample 41 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

42. Indian Dermatology Therapeutics Market Analysis 8. Healthcare Policy and Regulatory Landscape

43. 8.1 Regulatory Framework of India Dermatology Therapeutics Market The journey that culminated in the formation of IADVL as we know it today took its first flight in 1947 when Dr. UB Narayan Rao, conceived the idea to create an association of Dermatologists and Venereologists The IndianAssociation of Dermatologists, Venereologists and Leprologists (IADVL), the largest representing official society of Indian Dermatologists was established in its present form on 28th January, 1973 Aframework regarding rules was approved on July 26, 1948 and the association started its work on establishing local branches in other states. IADVLalso happens to be the world’s 2nd largestAssociation of Dermatologists behind the American Academy of Dermatology IADVL is the national association of Indian medical specialists who manage patients with skin disorders, sexually transmitted infections (STIs) or leprosy. The association works for the betterment of the specialty by holding academic meetings, printing a journal (print version & online) 43 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

44. Regulatory Framework of India Dermatology Therapeutic Market The IndianAssociation of Dermatologists, Venereologists and Leprologists (IADVL) organization is • ever committed to serving the public in the domains of dermatology. In lieu of this, IADVL observes several days of clinical significance including Leprosy day, Vitiligo day, World Skin Health Day to name a few IADVL has a wing dedicated to Community outreach programs which not only help in taking • quality skin care to the rural remote areas but also promote awareness on skin hygiene, equipping the local medical personnel to manage the common skin conditions and to refer the complicated cases to higher referral centers Indian Dermatology Online Journal (IDOJ) is a bimonthly open access print journal of Indian • Association of Dermatologists, Venereologists and Leprologists (IADVL) 44 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

45. Indian Dermatology Therapeutics Market Analysis 9. Factors Driving Future Growth

46. 9. Future Opportunities The new vendors within the Dermatology Diagnostic Devices and Therapeutics market face powerful competition from established international vendors as they struggle with technological innovations, dependability, and quality problems . The Indian Journal of Dermatology has always played a progressive role of acting as a medium for the ever- changing developments of scientific research in dermatology in this part of the world The prime strategically activities within the market are initiated by the key players which incorporate product developments, mergers, and acquisitions, partnerships, etc. Future Opportunities 46 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

47. Indian Dermatology Therapeutics Market Analysis 10. Conclusion

48. 10.1 Strategic Recommendations The importance of skin to the individual will not diminish, and funding agencies should recognize this. The costs of treating skin diseases will always be an issue, and the case for treating skin diseases will have to be made in a competitive world filled with many life- threatening diseases Dermatology in the new millennium must focus on the needs, hopes, and satisfaction of those who consider themselves to have skin liaments. Governments can change this by declaring some unidentified needs to be important and thus fundable, while others are deemed unimportant Dermatologists may themselves opt out of treating conditions which governance deems important.An example would be all breaks in surface continuity of the skin which other professions might wish to take over as leg ulcers, the diabetic foot ulcer, the pressure sore, or burns 48 A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential

49. Methodology & Scope

50. Research Methodology Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive overview of the competitive landscape to help our clients make informed strategic decisions We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government and regulatory published material, technical journals, trade magazines, and paid data sources For forecasting, the following parameters are considered: ❑ Market drivers and restraints along with their current and expected impacts ❑ Technological scenario and expected developments ❑ End use industry trends and dynamics ❑ Trends in the consumer behavior ❑ Regulatory scenario and expected developments ❑ Current capacity and expected capacity additions up to 2030 We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected market growth rate We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time- sensitive, reflecting the most recent value and volume of the market across regions All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs) The currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion ▪ ▪ ▪ ▪ ▪ ▪ ▪ A SampleReport on Indian DermatologyTherapeuticsMarketI Confidential